Humacyte, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 24.40K shares.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 4.10K shares, a 93.19% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 19.61K shares, a 96.11% decline from fiscal 2024.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 503.67K shares, a 13.26% increase from fiscal 2023.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 444.71K shares, a 97.33% increase from fiscal 2022.
- Humacyte, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 225.37K shares, a 19.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 24.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 28.50K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-13 | 4.10K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 4.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 19.61K shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 75.68K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 255.23K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 15.51K shares 10-Q · filed 2025-05-13 | 518.56K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 60.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 503.67K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 179.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 656.40K shares derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | 263.33K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 529.44K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 625.00 shares 10-Q · filed 2024-05-13 | 345.18K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 212.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 444.71K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 52.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 362.07K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 79.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 401.44K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 100.16K shares 10-Q · filed 2023-05-12 | 324.60K shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 130.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 225.37K shares 10-K · filed 2023-03-24 |
| 2022-09-30 | 91.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 95.39K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 2.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | |
| 2022-03-31 | 926.00 shares 10-Q · filed 2022-05-13 | |
| 2021-12-31 | 272.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 188.28K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |